



(Incorporated in the Cayman Islands with Limited Liability)

Stock Code: 0575

14 December 2020

ANNOUNCEMENT

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

OPERATIONS UPDATE ON **FORTACIN™**

The directors (the "Directors" or the "Board") of Regent Pacific Group Limited (the "Company" and collectively with its subsidiaries, the "Group") wish to inform the shareholders of the Company and potential investors of the following update in respect of its operations in relation Fortacin[™].

Further to the last operations update issued by the Company on 2 December 2020, the Directors are pleased to inform shareholders that Orient EuroPharma Co., Ltd. ("Orient EuroPharma"), the Group's commercial strategic partner for Taiwan, Hong Kong Special Administrative Region ("Hong Kong"), Macau Special Administrative Region ("Macau") and certain other countries in South East Asia, has informed the Group on 11 December 2020 that it has received marketing authorisation approval for Taiwan from the Taiwan Food and Drug Administration ("TFDA"). This is the final regulatory approval process required for the marketing, distribution and sale of Fortacin™ in Taiwan.



The regulatory approval from the TFDA has triggered a payment of US\$300,000 (or approximately HK\$2.34 million) to the Group.

Regent Pacific Group Limited 8th Floor, Henley Building 5 Queen's Road Central Hong Kong

Tel: (852) 2514 6111 Fax: (852) 2810 4792 | (852) 2509 0827 Email: info@regentpac.com Website: www.regentpac.com







The Group understands that Orient EuroPharma expects to launch Fortacin[™] in Taiwan, Hong Kong and Macau in 2021.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

Note: Unless otherwise specified herein, the amounts dominated into US\$ have been translated, for the purpose of illustration only, into HK\$ using the exchange rate of US\$1.00 = HK\$7.80.

On Behalf of the Board of **Regent Pacific Group Limited**

Jamie Gibson Executive Director

Directors of the Company:

James Mellon *(Chairman)** Jamie Gibson *(Chief Executive Officer)* David Comba[#] Julie Oates[#] Mark Searle[#] Jayne Sutcliffe*

- * Non-Executive Directors
- [#] Independent Non-Executive Directors

Hong Kong, 14 December 2020